BOSTON — In this exclusive video at The Liver Meeting, Andrew M. Hill, PhD, discusses data from a new study that show the price of a direct-acting antiviral generic regimen could be as low as $80 in the U.S. to cure hepatitis C virus infection in one patient.
“The potential to lower prices and treat far more people is enormous,” Hill said.
Hill and colleagues extracted data from an online database of Indian export ledgers for per-kilogram prices and volumes of direct-acting antiviral API’s exported from India between January and June 2016.
“We found these drugs are being exported from India as raw materials for very low prices,” Hill said.
No comments:
Post a Comment